keyword
MENU ▼
Read by QxMD icon Read
search

Risedronate

keyword
https://www.readbyqxmd.com/read/28318330/changes-of-bone-mineral-density-and-serum-pentosidine-during-a-27-month-follow-up-of-monthly-minodronate-in-osteoporotic-patients
#1
Tsuyoshi Ohishi, Tomotada Fujita, Daisuke Suzuki, Tatsuya Nishida, Kazufumi Yamamoto, Ryo Okabayashi, Hiroki Ushirozako, Tomohiro Banno, Yukihiro Matsuyama
PURPOSE: Monthly regimen of minodronate for osteoporosis more than two years has not been reported yet. The aim of this study is to elucidate the effect of monthly minodronate (M-MIN) on bone mineral density (BMD) and serum pentosidine (Pen) during 27 months. MATERIALS AND METHODS: The study consisted of 52 newly treated patients (73.3 ± 8.8 years) (new group) and 47 patients (75.9 ± 9.5 years) who were switched from either alendronate or risedronate (switch group)...
March 20, 2017: Endocrine Research
https://www.readbyqxmd.com/read/28304090/osteoporosis-treatment-efficacy-for-men-a-systematic-review-and-meta-analysis
#2
Smita Nayak, Susan L Greenspan
OBJECTIVES: To evaluate the efficacy of treatment options to reduce osteoporotic fracture risk in men. DESIGN: Systematic review and meta-analysis. SETTING: Randomized clinical trials that evaluated the efficacy of a treatment for osteoporosis or low bone mineral density for adult men and reported fracture outcomes. PARTICIPANTS: Men. MEASUREMENTS: PubMed, Embase, and the Cochrane Library databases were searched for relevant studies...
March 2017: Journal of the American Geriatrics Society
https://www.readbyqxmd.com/read/28296781/efficacy-and-safety-of-medical-therapy-for-low-bone-mineral-density-in-patients-with-crohn-disease-a-systematic-review-with-network-meta-analysis
#3
Xiaojing Zhao, Changcheng Zhou, Han Chen, Jingjing Ma, Yunjuan Zhu, Peixue Wang, Yi Zhang, Haiqin Ma, Hongjie Zhang
BACKGROUND: Low bone mineral density (BMD) is a frequent complication of inflammatory bowel disease (IBD), particularly in patients with Crohn disease (CD). The aim of our study is to determine the efficacy and safety of different drugs used to treat low BMD in patients with CD. METHODS: PUBMED/MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials were searched for eligible studies. A random-effects model within a Bayesian framework was applied to compare treatment effects as standardized mean difference (SMD) with their corresponding 95% credible interval (CrI), while odds ratio (OR) was applied to compare adverse events with 95% CrI...
March 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28283937/effect-of-bisphosphonate-initiation-at-week-2-versus-week-12-on-short-term-functional-recovery-after-femoral-neck-fracture-a-randomized-controlled-trial
#4
Aasis Unnanuntana, Panai Laohaprasitiporn, Atthakorn Jarusriwanna
The appropriate time to initiate bisphosphonate treatment after a fragility fracture has not yet been established. In this study, we found no significant differences in short-term functional recovery between femoral neck fracture patients who received bisphosphonate treatment at 2 versus 12 weeks after hemiarthroplasty. INTRODUCTION: Bisphosphonate is the mainstay therapy for prevention and treatment of osteoporosis. The aim of this study was to investigate the effect of bisphosphonate initiation on short-term functional recovery in femoral neck fracture patients at 2 versus 12 weeks after hemiarthroplasty...
December 2017: Archives of Osteoporosis
https://www.readbyqxmd.com/read/28265719/health-state-utility-values-and-patient-reported-outcomes-before-and-after-vertebral-and-non-vertebral-fractures-in-an-osteoporosis-clinical-trial
#5
T Imai, S Tanaka, K Kawakami, T Miyazaki, H Hagino, M Shiraki
We assessed the health state utility value (HSUV) reductions associated with vertebral fractures using data collected in the Japanese Osteoporosis Intervention Trial-03 (JOINT-03). Our analysis revealed that assessment of HSUVs after morphometric vertebral fracture is important to capture the burden of vertebral fractures. INTRODUCTION: Evaluation of the HSUV after fracture is important to calculate the quality-adjusted life years (QALYs) of osteoporosis patients, which is essential information in the context of health economic evaluation...
March 6, 2017: Osteoporosis International
https://www.readbyqxmd.com/read/28243883/two-year-persistence-and-compliance-with-osteoporosis-therapies-among-postmenopausal-women-in-a-commercially-insured-population-in-the-united-states
#6
Emily Durden, Lionel Pinto, Lorena Lopez-Gonzalez, Paul Juneau, Richard Barron
This retrospective, observational study assessed 2-year persistence and compliance by treatment, route of administration, and dosing frequency in postmenopausal women initiating a new osteoporosis therapy. Two-year persistence and compliance rates were higher in women receiving injectables compared with oral agents. PURPOSE: This study extends previous studies limited to 1-year follow-up by examining persistence with osteoporosis therapies over a 2-year period and compares short- and long-term trends in persistence and compliance among postmenopausal women with commercial or Medicare supplemental insurance in the USA...
December 2017: Archives of Osteoporosis
https://www.readbyqxmd.com/read/28243105/short-term-bisphosphonate-treatment-reduces-serum-25-oh-vitamin-d3-and-alters-values-of-parathyroid-hormone-pentosidine-and-bone-metabolic-markers
#7
Mikio Kamimura, Shigeharu Uchiyama, Yukio Nakamura, Shota Ikegami, Keijiro Mukaiyama, Hiroyuki Kato
This study aimed to clarify the effects of short-term bisphosphonate (BP) administration in Japanese osteoporotic patients retrospectively. Daily minodronate (MIN) at 1 mg/day (MIN group) or weekly risedronate (RIS) at 17.5 mg/week (RIS group) was primarily prescribed for each patient. We analyzed the laboratory data of 35 cases (18 of MIN and 17 of RIS) before the start of treatment and at 4 months afterward. The changes in 25(OH)D3, whole parathyroid hormone (PTH), serum pentosidine, and the bone turnover markers urinary cross-linked N-telopeptide of type I collagen (NTX), serum tartrate-resistant acid phosphatase (TRACP)-5b, bone-specific alkaline phosphatase (BAP), and undercarboxylated osteocalcin were evaluated...
2017: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/28235624/design-of-novel-injectable-in-situ-forming-scaffolds-for-non-surgical-treatment-of-periapical-lesions-in-vitro-and-in-vivo-evaluation
#8
Rehab N Shamma, Nermeen A Elkasabgy, Azza A Mahmoud, Shaimaa I Gawdat, Mohamed M Kataia, Mohamed A Abdel Hamid
Periapical lesions are considered one of the common pathological conditions affecting alveolar bone. The primary focus of this study was to investigate the effectiveness of formulating an injectable in-situ forming scaffold-loaded with risedronate (bone resorption inhibitor) and with lornoxicam (anti-inflammatory drug) for the non-surgical treatment of periapical lesions. The scaffolds were prepared using solvent-induced phase inversion technique. Two insoluble copolymers were investigated namely; PLGA (ester-terminal) and PLGA-A (acid-terminal), additionally, SAIB was added as a high viscosity water-insoluble carrier...
February 21, 2017: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/28201994/risedronate-therapy-in-patients-with-mild-to-moderate-chronic-kidney-disease-with-osteoporosis-post-hoc-analysis-of-data-from-the-risedronate-phase-iii-clinical-trials
#9
Takashi Shigematsu, Ryoichi Muraoka, Toshitsugu Sugimoto, Yoshiki Nishizawa
BACKGROUND: The clinical effect of bisphosphonate treatment has not been clearly evaluated by kidney function in Japanese Chronic Kidney Disease (CKD) patients with osteoporosis. This study analyzed the data from three risedronate Japanese phase III trials. The clinical effect of risedronate therapy was evaluated in CKD patients with osteoporosis. METHODS: The Japanese clinical trials involved 852 subjects who received risedronate (2.5 mg once daily or 17.5 mg once weekly) and whose estimated glomerular filtration rate (eGFR) were calculable and at ≥ 30 mL/min...
February 15, 2017: BMC Nephrology
https://www.readbyqxmd.com/read/28123122/-evidence-for-positive-effects-of-long-term-bisphosphonate-administration
#10
Hiroshi Hagino
Long-term treatment studies on the use of bisphosphonate(BP)for more than 5 years have been reported for alendronate, risedronate, and zoledronic acid. Bone mineral density(BMD)increases over the long term;however, a large increase has been observed over a 2 to 3 year period after initiation of BP treatment followed by gradual BMD increase and achieving a state of stability. After an initial reduction, the levels of bone remodeling markers remained stable within the premenopausal range during long-term BP treatment...
2017: Clinical Calcium
https://www.readbyqxmd.com/read/28117876/interventions-to-prevent-and-treat-corticosteroid-induced-osteoporosis-and-prevent-osteoporotic-fractures-in-duchenne-muscular-dystrophy
#11
REVIEW
Jennifer M Bell, Michael D Shields, Janet Watters, Alistair Hamilton, Timothy Beringer, Mark Elliott, Rosaline Quinlivan, Sandya Tirupathi, Bronagh Blackwood
BACKGROUND: Corticosteroid treatment is considered the 'gold standard' for Duchenne muscular dystrophy (DMD); however, it is also known to induce osteoporosis and thus increase the risk of vertebral fragility fractures. Good practice in the care of those with DMD requires prevention of these adverse effects. Treatments to increase bone mineral density include bisphosphonates and vitamin D and calcium supplements, and in adolescents with pubertal delay, testosterone. Bone health management is an important part of lifelong care for patients with DMD...
January 24, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28069980/editor-response-retraction-risedronate-therapy-for-prevention-of-hip-fracture-after-stroke-in-elderly-women-risedronate-therapy-for-prevention-of-hip-fracture-after-stroke-in-elderly-women-reply-from-the-authors
#12
COMMENT
https://www.readbyqxmd.com/read/28069979/letter-re-retraction-risedronate-therapy-for-prevention-of-hip-fracture-after-stroke-in-elderly-women-risedronate-therapy-for-prevention-of-hip-fracture-after-stroke-in-elderly-women-reply-from-the-authors
#13
COMMENT
https://www.readbyqxmd.com/read/28049945/inflammatory-effects-of-nitrogen-containing-bisphosphonates-n-bps-modulation-by-non-n-bps
#14
Kazuhiro Shima, Masahiro Tsuchiya, Takefumi Oizumi, Teruko Takano-Yamamoto, Shunji Sugawara, Yasuo Endo
Bisphosphonates (BPs) are used against diseases with enhanced bone resorption. Those classed as nitrogen-containing BPs (N-BPs) exhibit much stronger anti-bone-resorptive effects than non-nitrogen-containing BPs (non-N-BPs). However, N-BPs carry the risk of inflammatory/necrotic side effects. Depending on their side-chains, BPs are divided structurally into cyclic and non-cyclic types. We previously found in mice that etidronate and clodronate (both non-cyclic non-N-BPs) could reduce the inflammatory effects of all three N-BPs tested (cyclic and non-cyclic types), possibly by inhibiting their entry into soft-tissue cells via SLC20 and/or SLC34 phosphate transporters...
2017: Biological & Pharmaceutical Bulletin
https://www.readbyqxmd.com/read/28019683/effect-of-teriparatide-or-risedronate-in-elderly-patients-with-a-recent-pertrochanteric-hip-fracture-final-results-of-a-78-week-randomized-clinical-trial
#15
Jorge Malouf-Sierra, Umberto Tarantino, Pedro A García-Hernández, Costantino Corradini, Søren Overgaard, Jan J Stepan, Lars Borris, Eric Lespessailles, Frede Frihagen, Kyriakos Papavasiliou, Helmut Petto, Per Aspenberg, José Ramón Caeiro, Fernando Marin
We present final results of a study comparing teriparatide 20 µg QD with risedronate 35 mg QW started within 2 weeks after surgery for a pertrochanteric hip fracture. Patients with BMD T-score ≤-2.0 and 25OHD >9.2 ng/mL were randomized to receive 26-week double-dummy treatment plus calcium and vitamin D, followed by 52-week open-label treatment with the same assigned active drug. Primary endpoint was change from baseline in lumbar spine (LS) BMD at 78 weeks. Secondary and exploratory endpoints were change in BMD at the proximal femur, function, hip pain (Charnley score and 100 mm Visual Analog Scale [VAS]), quality of life (short form-36), radiology outcomes, and safety...
December 26, 2016: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
https://www.readbyqxmd.com/read/27933174/a-case-of-hepatitis-c-associated-osteosclerosis-accelerated-bone-turnover-controlled-by-pulse-steroid-therapy
#16
Nobuhiro Miyamura, Shuhei Nishida, Mina Itasaka, Hirofumi Matsuda, Takeshi Ohtou, Yasuhiro Yamaguchi, Daisuke Inaba, Sadahiro Tamiya, Tetsuo Nakano
Hepatitis C-associated osteosclerosis (HCAO), a very rare disorder in which an extremely rapid bone turnover occurs and results in osteosclerosis, was acknowledged in 1990s as a new clinical entity with the unique bone disorder and definite link to chronic type C hepatitis, although the pathogenesis still remains unknown. Affected patients suffer from excruciating deep bone pains. We report the 19th case of HCAO with diagnosis confirmed by bone biopsy, and treated initially with a bisphosphonate, next with corticosteroids and finally with direct acting antivirals (DAA: sofosbuvir and ribavirin) for HCV infection...
2016: Endocrinology, Diabetes & Metabolism Case Reports
https://www.readbyqxmd.com/read/27900428/relationship-between-baseline-characteristics-and-response-to-risedronate-treatment-for-osteoporosis-data-from-three-japanese-phase-iii-trials
#17
T Mawatari, R Muraoka, Y Iwamoto
We evaluated the influence of baseline age, bone mineral density (BMD), and serum levels of vitamin D on the response to risedronate treatment. Risedronate consistently increased BMD, but our results suggest vitamin D supplementation may be necessary to achieve optimal treatment effect. Furthermore, early intervention may help prevent bone fractures. INTRODUCTION: We aimed to investigate the influence of baseline age, BMD, and vitamin D insufficiency on the response to risedronate treatment...
November 30, 2016: Osteoporosis International
https://www.readbyqxmd.com/read/27862203/production-quality-control-and-determination-of-human-absorbed-dose-of-no-carrier-added-177-lu-risedronate-for-bone-pain-palliation-therapy
#18
Nafise Salek, Mohsen Mehrabi, Simindokht Shirvani Arani, Ali Bahrami Samani, Mostafa Erfani, Sara Vosoghi, Mohammad Ghannadi Maragheh, Mojtaba Shamsaei
In this study, the radiocomplexation of risedronic acid, a potent bisphosphonate with a no carrier added (NCA) (177) Lu, was investigated and followed by quality control studies, biodistribution evaluation, and dosimetry study for human based on biodistribution data in Wistar rats. The moderate energy β(-) emitter, (177) Lu (T½  = 6.7 days, Eβmax  = 497 keV), has been considered as a potential agent for development of bone-seeking radiopharmaceuticals. Because the specific activity of the radiolabeled carrier molecules should be high, the NCA radionuclides have an effective role in nuclear medicine...
November 15, 2016: Journal of Labelled Compounds & Radiopharmaceuticals
https://www.readbyqxmd.com/read/27852903/effects-of-teriparatide-compared-with-risedronate-on-recovery-after-pertrochanteric-hip-fracture-results-of-a-randomized-active-controlled-double-blind-clinical-trial-at-26-weeks
#19
Per Aspenberg, Jorge Malouf, Umberto Tarantino, Pedro A García-Hernández, Costantino Corradini, Søren Overgaard, Jan J Stepan, Lars Borris, Eric Lespessailles, Frede Frihagen, Kyriakos Papavasiliou, Helmut Petto, José Ramón Caeiro, Fernando Marin
BACKGROUND: Osteoporosis drugs might affect fracture-healing. We therefore studied the effects of teriparatide in comparison with risedronate on recovery after pertrochanteric hip fractures. METHODS: The study was a randomized, multicenter, active-controlled, 78-week trial comparing teriparatide (20 μg/day) with risedronate (35 mg/week) initiated within 2 weeks after fixation of a low-trauma pertrochanteric hip fracture (AO/OTA 31-A1 or 31-A2). The main inclusion criteria were a bone mineral density T-score of ≤-2...
November 16, 2016: Journal of Bone and Joint Surgery. American Volume
https://www.readbyqxmd.com/read/27801641/a-systematic-review-and-economic-evaluation-of-bisphosphonates-for-the-prevention-of-fragility-fractures
#20
Sarah Davis, Marrissa Martyn-St James, Jean Sanderson, John Stevens, Edward Goka, Andrew Rawdin, Susi Sadler, Ruth Wong, Fiona Campbell, Matt Stevenson, Mark Strong, Peter Selby, Neil Gittoes
BACKGROUND: Fragility fractures are fractures that result from mechanical forces that would not ordinarily result in fracture. OBJECTIVES: To evaluate the clinical effectiveness and safety of bisphosphonates [alendronic acid (Fosamax(®) and Fosamax(®) Once Weekly, Merck Sharp & Dohme Ltd), risedronic acid (Actonel(®) and Actonel Once a Week(®), Warner Chilcott UK Ltd), ibandronic acid (Bonviva(®), Roche Products Ltd) and zoledronic acid (Aclasta(®), Novartis Pharmaceuticals UK Ltd)] for the prevention of fragility fracture and to assess their cost-effectiveness at varying levels of fracture risk...
October 2016: Health Technology Assessment: HTA
keyword
keyword
27345
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"